Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Precision Biosciences Inc (NQ: DTIL )

10.10 -0.07 (-0.69%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 16,867
Open 10.09
Bid (Size) 10.02 (3)
Ask (Size) 10.19 (14)
Prev. Close 10.17
Today's Range 9.990 - 10.43
52wk Range 8.250 - 19.43
Shares Outstanding 113,793,338
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Precision BioSciences to Present at the Upcoming JonesTrading Healthcare Seaside Summit
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences Announces its Addition to the Russell Microcap® Index
From Precision BioSciences, Inc.
Via Business Wire

Performance

YTD
-9.01%
-9.01%
1 Month
+5.54%
+5.54%
3 Month
+3.91%
+3.91%
6 Month
-7.28%
-7.28%
1 Year
-42.45%
-42.45%

More News

Read More
Precision BioSciences Announces Presentation at UMDF Mitochondrial Medicine 2024 Supporting Advancement of PBGENE-PMM Program Towards IND and/or CTA in 2025
From Precision BioSciences, Inc.
Via Business Wire
Deep Dive Into Precision BioSciences Stock: Analyst Perspectives (4 Ratings)
Via Benzinga
Earnings Preview: Precision BioSciences
Via Benzinga
Precision BioSciences Expands Hepatitis Scientific Advisory Board with Addition of World-Class Clinical Investigators Mark Sulkowski, M.D. and Jordan Feld, M.D., MPH, as PBGENE-HBV Program Nears Clinical Readiness
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences Presents New Preclinical Safety Data for PBGENE-HBV Clinical Candidate at the European Association for the Study of the Liver Congress
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences to Participate in Upcoming June Investor Conferences
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Precision BioSciences, Inc.
Via Business Wire
DTIL Stock Earnings: Precision BioSciences Beats EPS, Beats Revenue for Q1 2024
Via InvestorPlace
Precision BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences Announces Common Stock Purchase by Members of Management for $300,000 in a Private Placement
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences to Report First Quarter Results on May 13, 2024
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences Announces Receipt of FDA Fast Track Designation for ECUR-506, iECURE’s Program for the Treatment of Neonatal Onset Ornithine Transcarbamylase (OTC) Deficiency
From Precision BioSciences
Via Business Wire
Precision BioSciences Announces Late-Breaking Poster Presentation at the European Association for Study of the Liver (EASL) Congress 2024
From Precision BioSciences, Inc.
Via Business Wire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Precision BioSciences Announces Return of Programs and Conclusion of Collaboration with Prevail Therapeutics
From Precision BioSciences, Inc.
Via Business Wire
DTIL Stock Earnings: Precision BioSciences Misses EPS, Misses Revenue for Q4 2023
Via InvestorPlace
Precision BioSciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Business Update
From Precision BioSciences, Inc.
Via Business Wire
Earnings Scheduled For March 27, 2024
Via Benzinga
Precision BioSciences to Report Fourth Quarter and Fiscal Year 2023 Results on March 27, 2024
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences Presents Preclinical Data Highlighting PBGENE-PMM as a Potential Therapy for Primary Mitochondrial Myopathy
From Precision BioSciences
Via Business Wire
Precision BioSciences Announces MHRA Approval for Partner iECURE to Expand Phase 1/2 Clinical Trial of ARCUS Gene Editing Program in OTC Deficiency
From Precision BioSciences, Inc.
Via Business Wire
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Why Zscaler Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.